N/A
Manufactured by Advagen Pharma Ltd
56,602 FDA adverse event reports analyzed
Last updated: 2026-04-14
AMITRIPTYLINE HYDROCHLORIDE is a medication tracked in the FDA Adverse Event Reporting System (FAERS), manufactured by Advagen Pharma Ltd. The most commonly reported adverse reactions for AMITRIPTYLINE HYDROCHLORIDE include PAIN, NAUSEA, HEADACHE, FATIGUE, DYSPNOEA. This page provides a comprehensive breakdown of reported side effects, safety signals, patient demographics, and AI-powered safety analysis for AMITRIPTYLINE HYDROCHLORIDE.
Out of 16,373 classified reports for AMITRIPTYLINE HYDROCHLORIDE:
The FDA classifies an adverse event as “serious” if it results in death, hospitalization, disability, congenital anomaly, or requires intervention to prevent permanent damage.
Demographics reflect voluntary FDA adverse event reporting patterns and may not represent the full patient population.
This profile reflects 56,602 FDA FAERS reports that mention AMITRIPTYLINE HYDROCHLORIDE. Reporting is voluntary and does not prove that the drug caused any listed event.
Frequently reported terms in FAERS include PAIN, NAUSEA, HEADACHE, FATIGUE, DYSPNOEA, DIZZINESS. Rankings reflect reporting volume in this dataset, not confirmed side effect rates in the general population.
Labeling and FAERS entries often list Advagen Pharma Ltd in connection with AMITRIPTYLINE HYDROCHLORIDE. Always verify the specific product and NDC with your pharmacist.